Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 15 PMN ProMIS Neurosciences GAAP EPS of -$0.19
May 14 PMN ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14 SILO Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
May 13 AXSM 15 Most Depressed States in the US
May 13 NXL Nexalin Technology First Quarter 2024 Earnings: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)
May 12 EHAB Insider Spends US$82k Buying More Shares In Enhabit
May 11 EHAB Enhabit, Inc. (EHAB) Q1 2023 Earnings Call Transcript
May 11 AXSM Prediction: These 2 Growth Stocks Could Triple By 2030
May 10 EHAB Enhabit Inc (EHAB) Reports Mixed Q1 2024 Results: Challenges and Strategic Adjustments Highlighted
May 10 AXSM Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 9 EHAB AREX Capital Expresses Disappointment in Enhabit’s Strategic Review Conclusion
May 9 EHAB Enhabit challenged by hedge fund AREX Capital seeking seven board seats - report
May 9 NXL Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
May 9 AXSM Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 8 EHAB Enhabit (EHAB) Beats Q1 Earnings Estimates
May 8 EHAB Enhabit GAAP EPS of $0.01, revenue of $262.4M
May 8 EHAB Enhabit concludes review of strategic alternatives
May 8 EHAB Enhabit Concludes Review of Strategic Alternatives
May 8 EHAB Enhabit Reports First Quarter 2024 Financial Results
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags